α-synuclein
α-Syn
α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-synuclein regulates synaptic vesicle trafficking and subsequent neurotransmitter release. Genetics and neuropathology studies link α-synuclein to Parkinson's disease (PD) and other neurodegenerative disorders. Accumulation of misfolded oligomers and larger aggregates of α-synuclein defines multiple neurodegenerative diseases called synucleinopathies, but the mechanisms by which α-synuclein acts in neurodegeneration are unknown.
α-synuclein Isoform Specific Products
All Product Categories
-
α-synuclein Inhibitors
(117)
View all products
-
α-synuclein Antagonists
(2)
View all products
-
α-synuclein Activator
(1)
View all products
-
α-synuclein Modulators
(2)
View all products
-
α-synuclein Inducers
(2)
View all products
-
α-synuclein Degraders
(11)
View all products
-
α-synuclein Control
(1)
View all products
-
α-synuclein Ligands
(6)
View all products
-
α-synuclein Related Products (157)
Related Products (157)
-
α-synuclein Isoform Comparison
-
Hupehenine (Standard)
0 ImagesCat. No.: HY-N0413RCAS No.: 98243-57-3Hupehenine (Standard) is the analytical standard of Hupehenine (HY-N0413). This product is intended for research and analytical applications. Hupehenine is an orally active isosteroidal alkaloid that can be extracted from F. hupehensis. Hupehenine exhibits activities such as antitussive, expectorant, anticancer, and antiparasitic. In vitro, Hupehenine can also inhibit α-synuclein seeded fibril formation, making it applicable for the research of Parkinson's disease and other related disorders.
-
α-Synuclein aggregate binder 2
0 ImagesCat. No.: HY-176925CAS No.: 3056154-68-5α-Synuclein aggregate binder 2 (Compound 1) is a specific alpha-synuclein binder with a Ki of 1.6 nM. α-Synuclein aggregate binder 2 has a weak binding affinity for β-amyloid aggregates with a Ki of 295 nM. α-Synuclein aggregate binder 2 can be used as a tracer in Parkinson's disease.
-
α-Synuclein inhibitor 13
0 ImagesCat. No.: HY-163519α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research.
-
α-Synuclein inhibitor 5
0 ImagesCat. No.: HY-147667CAS No.: 2489813-11-6α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.22 μM and inhibition ratio at 30 μM of 94.3%.
-
PQM-164
0 ImagesCat. No.: HY-159152CAS No.: 2226535-25-5PQM-164 (Compound 3e) has antioxidant activity (IC50: 0.93 μM for DPPH radical). PQM-164 shows anti-inflammatory activity against 6-OHDA (HY-B1081A)-induced neuronal damage in activated microglial cells. PQM-164 decreases the accumulation of α-synuclein. PQM-164 promotes nuclear translocation of Nrf2 and its transcriptional activity. PQM-164 can be used for research of Parkinson’s disease.
-
DA5-CH
0 ImagesCat. No.: HY-P12141CAS No.: 2227651-65-0Synonyms: KP405DA5-CH (KP405) is a blood-brain barrier-permeable GLP-1/GIP receptor agonist. DA5-CH activates GLP-1 and GIP receptors, inhibits the NF-κB inflammatory pathway, reduces α-synuclein (α-synuclein) levels, restores the expression of tyrosine hydroxylase and neurotrophic factors, improves motor function, decreases amyloid plaques and phosphorylated tau protein levels in the hippocampus, restores synaptic plasticity, regulates the PI3K/AKT/GSK3β and CREB signaling pathways, and alleviates mitochondrial stress. DA5-CH can be used for research on Parkinson's disease and Alzheimer's disease.
-
6PPD-Q (Standard)
0 ImagesCat. No.: HY-153169RCAS No.: 2754428-18-56PPD-Q (Standard) is the analytical standard of 6PPD-Q (HY-153169). This product is intended for research and analytical applications. 6PPD-Q (6PPD-Quinone) is an environmental pollutant that can be detected in human urine and is widely present in the environment. 6PPD-Q targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1, with CNR2 exhibiting the highest binding affinity, potentially acting as a CNR2 receptor agonist to activate cannabinoid receptors. 6PPD-Q induces intestinal inflammation and barrier damage by disrupting mitochondrial function, reducing neuronal glycolysis metabolites and TCA cycle intermediates, and exacerbating α-synuclein (α-syn) aggregation. 6PPD-Q is applicable in research on environmental toxicology, neurodegenerative diseases, and inflammation-related disorders.
-
Semaglutide, Cy5 labeled
0 ImagesCat. No.: HY-114118F5Synonyms: Semaglutide-Cys(Cy5)Semaglutide, Cy5-labeled (Semaglutide-Cys(Cy5)) is a CY5 (HY-D0821) -labeled version of Semaglutide (HY-114118) (Ex/Em = 633/670 nm). Semaglutide, Cy5-labeled can be used for studies on Semaglutide receptor binding (GLP-1R), cellular uptake and endocytosis, in vivo tissue distribution, and the targeting efficiency of delivery systems.
-
Alpinin A
0 ImagesCat. No.: HY-N16524CAS No.: 2151847-03-7Alpinin A is a diarylheptanoid found in the rhizomes of Alpinia officinarum. Alpinin A can strongly inhibit the aggregation of α-synuclein with inhibition rate of 66% at 10 μM. Alpinin A can be used for the research of neurological disease, such as Parkinson’s disease.
-
D-685
0 ImagesCat. No.: HY-149065CAS No.: 2893801-00-6D-685, a prodrug of D-520, exhibits higher in vivo anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model than the parent D-520. D-685 reduces accumulation of human α-synuclein (α-syn) protein. D-685 exhibits facile brain penetration.
-
PROTAC α-synuclein degrader 1
0 ImagesCat. No.: HY-135999CAS No.: 2412273-73-3PROTAC α-synuclein degrader 1 is a α-synuclein PROTAC degrader that can recruit VHL. PROTAC α-synuclein degrader 1 induces ubiquitination and degradation of α-synuclein, and is applicable to researches on Parkinson's disease, Alzheimer's disease, dementia with Lewy bodies, multiple system atrophy, etc.
-
Semaglutide sodium
0 ImagesCat. No.: HY-114118CCAS No.: 2924330-56-1Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
-
Dopal (purity>80%)
0 ImagesCat. No.: HY-121252ACAS No.: 5707-55-1Dopal (purity>80%) is a metabolite and aldehyde neurotoxin of Dopamine (HY-B0451). Dopal (purity>80%) exhibits cytotoxicity, induces α-synuclein oligomerization and aggregation, and is closely associated with the pathogenesis of Parkinson's disease. Dopal (purity>80%) can be used in research related to Parkinson's disease.
-
α-Synuclein (67-78) (human)
0 ImagesCat. No.: HY-P5043CAS No.: 2243206-99-5α-Synuclein (67-78) (human) is the 67-78 fragment of α-Synuclein. α-Synuclein (67-78) (human) promotes network activity drive and blocks KCl-induced syt1L-ab uptake.
-
Aerophobin-2
0 ImagesCat. No.: HY-130398CAS No.: 87075-23-8Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy.
-
α-Synuclein (61-75)
0 ImagesCat. No.: HY-P3140CAS No.: 440645-08-9α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD).
-
NS163
0 ImagesCat. No.: HY-163613CAS No.: 3069546-41-1NS163 is a α-Synuclein aggregation antagonist. NS163 can be used for study of Parkinson’s disease.
-
CLR01 sodium
0 ImagesCat. No.: HY-182304CAS No.: 1338489-62-5CLR01 sodium is a blood-brain barrier-permeable anti-aggregation agent. CLR01 sodium inhibits the de novo aggregation of Amyloid-β 40/42, α-synuclein, IAPP, tau protein and SOD1. CLR01 sodium reduces amyloid plaque burden in the cortex of triple-transgenic mice and improves the memory and motor abilities of these mice. CLR01 sodium can be used in research related to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
-
α-Synuclein inhibitor 14
0 ImagesCat. No.: HY-N15613CAS No.: 408324-13-0α-Synuclein inhibitor 14 (Compound 3) is a diarylheptanoid that can be isolated from Alpinia officinarum. α-Synuclein inhibitor 14 can inhibit the aggregation of α-synuclein, with an inhibition rate of 72.4% at a concentration of 10 μM. α-Synuclein inhibitor 14 can be used in the research of neurodegenerative diseases such as Parkinson's disease.
-
Arg-PEG1-Tαsyn
0 ImagesCat. No.: HY-180976Arg-PEG1-Tαsyn is an α-syn PROTAC degrader with a DC50 of 0.28 μM in U251 cells. Arg-PEG1-Tαsyn employs the amino acid arginine (Arg) as the E3 ligase UBR1 ligand and a benzothiazole-aniline variant as the warhead for α-syn. Arg-PEG1-Tαsyn significantly reduces α-syn aggregates and improves the dopaminergic neuronal impairment and the locomotion with safety profile in vivo.Arg-PEG1-Tαsyn shows the high degradation effect in mammalian cells for both wild-type α-syn and the α-syn (A53T) mutant. Arg-PEG1-Tαsyn can be used for Parkinson’s disease research.
